Literature DB >> 26377359

Heparin: 100 years of pleiotropic effects.

Adilson Ferraz Paschoa1.   

Abstract

Heparin is a glycosaminoglycan with anticoagulant properties and antiinflammatory effects. The discovery of heparin approaches its 100th year and its antiinflammatory properties still draws much attention and anticipation to new possibilities of use and the likelihood of developing heparin-like drugs that lacked the anticoagulation effects. It is known that heparins limit the embolization and the extension of the thrombus, although they do not promote its complete lysis in most cases. The complexity and pleiotropic characteristics of these glycosaminoglycans still challenge science, to the point in which approaches hitherto unusual appear repeatedly in the literature. New indications, accompanied by longtime consecrated others, dismantle the idea of an outdated medication and create high expectations for the near future. The objective of this review is to analyze the pleiotropic effects of heparin and its use in several diseases, highlighting its safety and effectiveness.

Entities:  

Keywords:  Heparin; Pleiotropic effects; Thrombolysis; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26377359     DOI: 10.1007/s11239-015-1261-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  65 in total

Review 1.  Asthma and coagulation.

Authors:  J Daan de Boer; Christof J Majoor; Cornelis van 't Veer; Elisabeth H D Bel; Tom van der Poll
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

Review 2.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 3.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines.

Authors:  T M Handel; Z Johnson; S E Crown; E K Lau; A E Proudfoot
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

4.  Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group.

Authors:  B Lebeau; C Chastang; J M Brechot; F Capron; B Dautzenberg; C Delaisements; M Mornet; J Brun; J P Hurdebourcq; E Lemarie
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

5.  Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis.

Authors:  C Vancheri; C Mastruzzo; F Armato; V Tomaselli; S Magrì; M P Pistorio; M LaMicela; L D'amico; N Crimi
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

Review 6.  The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials.

Authors:  D Sanford; A Naidu; N Alizadeh; A Lazo-Langner
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 7.  Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review.

Authors:  Russell D Hull; Jane Liang; Grace Townshend
Journal:  Am J Med       Date:  2011-08       Impact factor: 4.965

8.  Size-fractionated heparins have differential effects on human neutrophil function in vitro.

Authors:  R Lever; W T Lo; M Faraidoun; V Amin; R A Brown; J Gallagher; C P Page
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

9.  Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Authors:  Debra A Cockayne; Donavan T Cheng; Benjamin Waschki; Sriram Sridhar; Palanikumar Ravindran; Holly Hilton; Galina Kourteva; Hans Bitter; Sreekumar G Pillai; Sudha Visvanathan; Kai-Christian Müller; Olaf Holz; Helgo Magnussen; Henrik Watz; Jay S Fine
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

Review 10.  Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review.

Authors:  Sarah Mousavi; Mandana Moradi; Tina Khorshidahmad; Maryam Motamedi
Journal:  Adv Pharmacol Sci       Date:  2015-05-12
View more
  4 in total

1.  Unfractionated heparin after TBI reduces in vivo cerebrovascular inflammation, brain edema and accelerates cognitive recovery.

Authors:  Katsuhiro Nagata; Kenichiro Kumasaka; Kevin D Browne; Shengjie Li; Jesse St-Pierre; John Cognetti; Joshua Marks; Victoria E Johnson; Douglas H Smith; Jose L Pascual
Journal:  J Trauma Acute Care Surg       Date:  2016-12       Impact factor: 3.313

Review 2.  The Role of Heparin in COVID-19: An Update after Two Years of Pandemics.

Authors:  Marco Mangiafico; Andrea Caff; Luca Costanzo
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

Review 3.  Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Authors:  I García-Escobar; C Beato-Zambrano; J Muñoz Langa; E Brozos Vázquez; B Obispo Portero; D Gutiérrez-Abad; A J Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2018-02-22       Impact factor: 3.405

4.  Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study.

Authors:  Giuseppe Cardillo; Giuseppe Vito Viggiano; Vincenzo Russo; Sara Mangiacapra; Antonella Cavalli; Giampiero Castaldo; Federica Agrusta; Annamaria Bellizzi; Maria Amitrano; Mariateresa Iannuzzo; Clara Sacco; Corrado Lodigiani; Andrea Fontanella; Pierpaolo Di Micco
Journal:  J Blood Med       Date:  2021-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.